NYMOX Pharmaceutical provides update on Phase 3 trials for BPH drug
Nymox Pharmaceutical provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The first Safety Monitoring Committee meeting of 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated an acceptable ongoing safety evaluation of the trials to date. Patient recruitment and trial activities for pivotal U.S. studies NX02-0017 and NX02-0018 are proceeding at over 60 well-known urology investigative sites throughout the U.S. The participating centers continue to evaluate and enroll patients and accrual is progressing well. The current Phase 3 trials incorporate specific protocol design recommendations made by the FDA at the earlier EOP2 meeting with the company. :theflyonthewall.com
News For NYMX From The Last 14 Days
Check below for free stories on NYMX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
